了解创新者业务关切点、富于创造力的资深代讼人
自首次参加ANDA诉讼以来,飞翰一举奠定在联邦地区法院和美国联邦巡回上诉法院代理创新制药公司诉讼的领导地位。我们的成功源于一支经验丰富、技术精湛的律师团队,他们了解创新制药公司的长期计划以及《哈奇-维克斯曼》法案(Hatch-Waxman Act)框架下ANDA诉讼的法律细节和药物专利法的细微之处。近五年来,我们的律师在近400起ANDA诉讼中代表过30家品牌公司,其中涉及Prolensa®, Relistor® 皮下制剂、Relistor® 片剂、Cymbalta®和Abilify®等革命性药物。
正因为飞翰被公认为保护重磅型产品的首选律师事务所,而且我们的许多诉讼案件都属于“关乎公司存亡”的委托,我们认识到,所有产品无论销售额如何,对客户都十分重要,因此通过量身打造我们的诉讼团队,最有效地保护客户产品。凭借事务所的规模以及深厚的原研药ADNA诉讼经验,我们有能力以最具成本效益的方式,针对案件所涉及的技术量身打造我们的团队,从而达到客户的目标。我们与客户携手合作,制定创新、协同和成功的诉讼策略。
利用深层次科学构建有说服力的立场
ANDA案件的胜败通常取决于律师事务所能否掌握构成专利发明基础的科学、并以令人信服的方式呈现该技术的能力。飞翰拥有约85名持有生物或化学科学高级学位的专业人员,有能力利用基础的科学构建胜诉立场。大约三分之一的飞翰执业律师拥有相关科学专业的博士学位,大部分律师在加入飞翰律师事务所之前曾在业内、高校任职,或在美国专利商标局(USPTO)担任审查员。凭借技术专长,我们能够与发明者和专家无缝联系,利用细微且重要的细节,打造简明、有说服力且易于理解的论据。
早期准备十分关键
ANDA诉讼获胜往往始于诉讼开始前数月甚至数年。客户在专利挑战(Paragraph IV)之前即委托我们分析相关专利组合,确定和获得最佳申诉范围,评估、评价和解决潜在漏洞,包括在美国专利商标局的对质式诉讼程序中可能遭受质疑的漏洞。不论在等待专利挑战通知函过程中,或者仍处于临床试验后期,都应该尽早开始诉讼准备工作。
在上诉中脱颖而出
飞翰律师在美国联邦巡回上诉法院提交案由和申辩的数量达百余件,几乎超过其他任何律师事务所,并在Abilify®、Claritin®、Crestor®、Naprelan®、Strattera®和Zyprexa®等创新药物保护案件中胜诉。飞翰律师事务所约40名律师曾在联邦巡回法院或其前身法院担任法官助理职务。他们作为助理与法官紧密合作,协助起草判决意见,深入了解法院的审议进程和程序,进一步加强我们的经验深度和对法律的敏锐认识。凭借无与伦比的上诉经验和行业专长,我们能够在整个ANDA流程中为客户的药品创新保驾护航。
2:23-cv-00094, 2:23-cv-02364, D.N.J., Judges Cecchi, Padin, Wettre
1:18-cv-01395, D. Del., Judge Connolly
1:18-cv-00664, D. Del., Judge Andrews
3:21-cv-16766, D.N.J., Judges Kirsch, Singh
1:21-cv-00870, D. Del., Judge Hall
Successfully led Kaken and Bausch Health Care in inter partes review (IPR) proceedings, district court litigation, and Federal Circuit appeal related to patent covering Kaken and Bausch Health Care’s Jublia® (efinaconazole) product for the treatment of onychomycosis.
3:18-cv-13635, D.N.J., Judges Martinotti, Goodman
18-2232, Fed. Cir., Judges Newman, O'Malley, Taranto
IPR2017-00190, PTAB, Judges Mitchell, Franklin, Pollock
IPR2017-01429, PTAB, Judges Mitchell, Franklin, Pollock
Conference
3rd Annual Passport to Proficiency on the Essentials of Hatch-Waxman and BPCIA
October 10-26, 2023
Virtual
Federal Circuit IP Blog
August 4, 2023
Prosecution First Blog
Obviousness and Written Description Take Down an Infringed Patent
June 30, 2023
Federal Circuit IP Blog
Parkinson’s Patent Invalid Based on Obviousness of Overlapping Ranges
April 20, 2023
March 22-23, 2023
Virtual
Award/Ranking
Five Finnegan Partners Named 2024 Leading Litigators in America by Lawdragon
October 30, 2023
Award/Ranking
Finnegan Receives Tier 1 Benchmark Litigation Rankings; Nine Attorneys Named Litigation Stars
October 5, 2023
Award/Ranking
Finnegan Shortlisted in 10 Categories in the LMG Life Sciences Awards 2023
July 25, 2023
Press Release
Finnegan Victory for BioDelivery Sciences International in ANDA Case Affirmed
December 29, 2022
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.